Fifteen residues is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
== History == KNX-100 was first described in the scientific literature by 2012. It was originated at the University of Sydney by Iain McGregor and Michael Bowen and colleagues and is under development by Kinoxis Therapeutics in partnership with Boehringer Ingelheim. In 2018, it was reported that KNX-100 had been under development for more than a decade. The drug was identified via a phenotypic screen of compounds derived from a fragment-based drug discovery system targeting the oxytocin system. In January 2026, it was disclosed that KNX-100's mechanism of action is inhibition of the enzyme arachidonate 15-lipoxygenase (ALOX15).
=== Immediate effects === Users report feelings of relaxation, sharpness, calmness, and alertness. Those new to smoking may experience nausea, dizziness, coughing and a bad taste in the mouth, and a number of adverse cardio-vascular effects such as increased blood pressure, narrowed arteries, rapid heart beat. Generally, the unpleasant symptoms will eventually vanish over time, with repeated use, as the body builds a tolerance to the chemicals in the cigarettes, such as nicotine. While the functional changes are mostly reversible after quitting, the structural cardiovascular damage is not fully reversible.
=== Energy source === Anabolism is powered by catabolism, where large molecules are broken down into smaller parts and then used up in cellular respiration. Many anabolic processes are powered by the cleavage of adenosine triphosphate (ATP). Anabolism usually involves reduction and decreases entropy, making it unfavorable without energy input. The starting materials, called the precursor molecules, are joined using the chemical energy made available from hydrolyzing ATP, reducing the cofactors NAD+, NADP+, and FAD, or performing other favorable side reactions. Occasionally it can also be driven by entropy without energy input, in cases like the formation of the phospholipid bilayer of a cell, where hydrophobic interactions aggregate the molecules.
Hunt Sahir Field in December 1971. In September 1973, all foreign oil producers in Libya saw 51 per cent of their operation nationalized. Among the companies that were partially nationalized was Armand Hammer's Occidental Petroleum. For Gaddafi, this was an essential step towards socialism. It proved an economic success; while gross domestic product had been $3.8 billion in 1969, it had risen to $13.7 billion in 1974, and $24.5 billion in 1979. In turn, Libyan standards of life greatly improved over the first decade of Gaddafi's administration, and by 1979 the average per-capita income was at $8,170, up from $40 in 1951; above that of many industrialized countries like Italy and the UK. In 1969, the government ordered all foreign owned banks to close down or convert to joint-stock operations.
Barotrauma typically occurs when the organism is exposed to a significant change in ambient pressure, such as when a scuba diver, a free-diver or an airplane passenger ascends or descends or during uncontrolled decompression of a pressure vessel such as a diving chamber or pressurized aircraft, but can also be caused by a shock wave. Ventilator-induced lung injury (VILI) is a condition caused by over-expansion of the lungs by mechanical ventilation used when the body is unable to breathe for itself and is associated with relatively large tidal volumes and relatively high peak pressures. Barotrauma due to overexpansion of an internal gas-filled space may also be termed volutrauma.
Sources: en.wikipedia.org
An accompanying study showed that the artificial WW domains were functionally similar to natural WW domains in ligand binding affinity and specificity. In de novo protein structure prediction, it has been shown that, when combined with a simple residue-residue distance metric, SCA-based scoring can fairly accurately distinguish native from non-native protein folds.
Because the let-7 family comprises multiple isoforms that share a conserved seed sequence but differ outside it, the choice of isoform influences which targets are most effectively regulated and to what degree, underscoring that even closely related miRNA family members are not functionally interchangeable. The effects of miRNA dysregulation of gene expression also seem to be important in neuropsychiatric disorders, such as schizophrenia, bipolar disorder, major depression, Parkinson's disease, Alzheimer's disease and autism spectrum disorders.
=== Facilitates the quaternary structure === The enzyme cytochrome c oxidase, also known as Complex IV, is a large transmembrane protein complex found in mitochondria and bacteria. It is the last enzyme in the respiratory electron transport chain located in the inner mitochondrial or bacterial membrane. It receives an electron from each of four cytochrome c molecules, and transfers them to one oxygen molecule, converting molecular oxygen to two molecules of water. Complex IV has been shown to require two associated CL molecules in order to maintain its full enzymatic function. Cytochrome bc1 (Complex III) also needs cardiolipin to maintain its quaternary structure and functional role. Complex V of the oxidative phosphorylation machinery also displays high binding affinity for CL, binding four molecules of CL per molecule of complex V.
Voltage – Regulated by the difference in voltage across the membrane Stress – Regulated by physical pressure on the transporter (as in the cochlea of the ear) Ligand – Regulated by the binding of a ligand to either the intracellular or extracellular side of the cell Uniporters are found in mitochondria, plasma membranes and neurons.The uniporter in the mitochondria is responsible for calcium uptake. The calcium channels are used for cell signaling and triggering apoptosis. The calcium uniporter transports calcium across the inner mitochondrial membrane and is activated when calcium rises above a certain concentration. The amino acid transporters function in transporting neutral amino acids for neurotransmitter production in brain cells. Voltage-gated potassium channels are also uniporters found in neurons and are essential for action potentials. This channel is activated by a voltage gradient created by sodium-potassium pumps. When the membrane reaches a certain voltage, the channels open, which depolarizes the membrane, leading to an action potential being sent down the membrane. Glucose transporters are found in the plasma membrane and play a role in transporting glucose. They help to bring glucose from the blood or extracellular space into cells usually to be utilized for metabolic processes in generating energy. Uniporters are essential for certain physiological processes in cells, such as nutrient uptake, waste removal, and maintenance of ionic balance.
The African countries of Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Democratic Republic of the Congo, Republic of the Congo, Côte d'Ivoire, Gabon, Ghana, Guinea-Bissau, Mali, Niger, Sierra Leone and Togo, South Sudan and Uganda, along with French Guiana in South America, require all incoming passengers older than nine months to one year, to have a current International Certificate of Vaccination or Prophylaxis. Some other countries require vaccination only if the passenger is coming from an infected area or has visited one recently or has transited for 12 hours in those countries: Algeria, Botswana, Cabo Verde, Chad, Djibouti, Egypt, Eswatini, Ethiopia, Gambia, Ghana, Guinea, Lesotho, Libya, Equatorial Guinea, Eritrea, Madagascar, Malawi, Mauritania, Mauritius, Mozambique, Namibia, Nigeria, Papua New Guinea, Seychelles, Somalia, South Africa, Sudan, Tunisia, Uganda, Tanzania, Zambia and Zimbabwe.
Sources: en.wikipedia.org
All the Rh(III) halides are known. Synthesis of many rhodium complexes begin with RhCl3·3H2O, the hydrated trichloride, but RhCl3, the anhydrous form, is largely inert. Other rhodium(III) chlorides include sodium hexachlororhodate, Na3RhCl6, and pentaamminechlororhodium dichloride, [Rh(NH3)5Cl]Cl2. They are used in the recycling and purification of this very expensive metal. Heating a methanolic solution of hydrated rhodium trichloride with sodium acetate gives the blue-green rhodium(II) acetate, Rh2(O2CCH3)4, which features a Rh–Rh bond. This complex and related rhodium(II) trifluoroacetate have attracted attention as catalysts for cyclopropanation reactions. Heating treated with triphenylphosphine in ethanol, hydrated rhodium trichloride converts to RhCl(P(C6H5)3)3. This square planar complex, which is known as Wilkinson's catalyst, is a common and early example of a well-defined homogeneous catalyst for hydrogenation of alkenes.
An alternative method for removal of caffeine from coffee is the Swiss Water process. This process uses no organic solvents, and instead only water is used to decaffeinate beans. It is a technique first developed in Switzerland in 1933, and commercialized by Coffex S.A. in 1980. The Swiss Water process was then introduced by The Swiss Water Decaffeinated Coffee Company of Burnaby, British Columbia, in 1988. The process uses green coffee extract (GCE) for the caffeine extraction mechanism. Green coffee extract is a solution containing the water-soluble components of green coffee except for the caffeine, obtained by soaking green coffee beans in hot water, then filtering through an activated charcoal filter to remove the caffeine molecules. Fresh beans containing both caffeine and the other components are added to the GCE solution, where the gradient pressure difference between the GCE (which is caffeine-lean) and the green coffee (which is caffeine-rich) causes the caffeine molecules to migrate from the green coffee into the GCE. Because GCE is saturated with the other water-soluble components of green coffee, only the caffeine molecules migrate to the GCE; the other water-soluble coffee elements are retained in the green coffee. The newly caffeine-rich GCE solution is then passed through the activated carbon filters to remove the caffeine again, and the process is repeated. The continuous batch process takes 8–10 hours to meet the final residual decaffeinated target. Food engineer Torunn Atteraas Garin also developed a process to remove caffeine from coffee.
==== Statins ==== Statins, also known as beta-hydroxy-beta-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitors, are the first-line drugs for hypercholesterolaemia. Examples of this drug class are atorvastatin, rosuvastatin, fluvastatin, simvastatin, pravastatin and lovastatin. Most efficacious in lowering LDL-C levels, statins block the action of HMG-CoA reductase through competitive inhibition. HMG-CoA reductase, an enzyme found in hepatocytes, is responsible for the conversion of HMG-CoA to mevalonic acid for cholesterol biosynthesis. Inhibition of this enzyme reduces the synthesis and thus, availability of endogenous cholesterol. This reduction in intracellular cholesterol, in turn, causes an increase in the number of LDL receptors on hepatic cells. The elevation of LDL receptor expression decreases the plasma LDL-C level by promoting hepatic uptake of LDL from circulation.
A mortar attack by insurgents killed six civilians and wounded 14 whereas two policemen were injured by sniper fire during the operation in Hangu, following which Pakistani forces took control of the area. Two children were killed and four were injured in crossfire during a skirmish in Bajaur District. On 7-8 May 2026, Pakistani forces conducted two operations in Dera Ismail Khan and Tank District, killing five militants. On 8 May 2026, eight civilians were injured in a quadcopter strike in Bannu District. A police constable was killed by militants after his abduction in Bajaur. On 9 May 2026, a car bomb exploded at a Pakistani checkpoint in Bannu, leaving at least 21 dead. Ittehad-ul-Mujahideen Pakistan, a Pakistani Taliban splinter group, claimed responsibility for the attack. On 10 May 2026, an Al-Qaeda affiliate was arrested by CTD in Pakpattan District. Pakistani forces killed seven militants including two key commanders, and destroyed militant infrastructure in a clearance operation in North Waziristan District. On 11 May 2026, a civilian was killed while foiling a suicide bombing in Attock District. On 12 May 2025, UNAMA stated that 372 civilians were killed and 397 had been wounded in Pakistani strikes on Afghanistan. On 13 May 2026, nine people including two traffic police personnel were killed and 33 injured in a VBIED attack by TTP in Lakki Marwat District, TTP militants also blew up a bridge in Bannu District. TTP militants captured a bank van and robbed PKR 80M. CM Khyber Pakhtunkhwa claimed that 80% of militants operating in the province were foreigners.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.